• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

1型糖原贮积病患者合并糖尿病:一例报告

Diabetes mellitus in a patient with glycogen storage disease type Ia: a case report.

作者信息

Cohn Aviva, Ohri Anupam

机构信息

Department of Internal Medicine, Rutgers Robert Wood Johnson Medical School, 1 RWJ Place, MEB 486 PO Box 19, New Brunswick, NJ, 08903, USA.

出版信息

J Med Case Rep. 2017 Nov 12;11(1):319. doi: 10.1186/s13256-017-1462-5.

DOI:10.1186/s13256-017-1462-5
PMID:29127952
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5682031/
Abstract

BACKGROUND

Glycogen storage disease type Ia is a genetic disorder that is associated with persistent fasting hypoglycemia and the inability to produce endogenous glucose. The development of diabetes with glycogen storage disease is exceedingly rare. The underlying pathogenesis for developing diabetes in these patients is unclear, and there are no guidelines for treatment.

CASE PRESENTATION

We describe a case of a 34-year-old woman of South Asian descent with glycogen storage disease type Ia, who developed uncontrolled diabetes mellitus as a young adult. Hyperglycemia was noted after childbirth, and worsened years later. Treatment for diabetes was difficult due to risks of hypoglycemia from her underlying glycogen storage disease. With minimal hypoglycemic events, the patient's blood glucose improved with exercise in combination with a sodium-glucose co-transporter 2 inhibitor and an alpha glucosidase inhibitor.

CONCLUSION

We report a rare case of diabetes in the setting of glycogen storage disease-Ia. Based on the literature, there appears to be a relationship between glycogen storage disease and metabolic syndrome, which likely plays a role in the pathogenesis. The management of glycemic control remains a clinical challenge, requiring management of both fasting hypoglycemia from glycogen storage disease, as well as post-prandial hyperglycemia from diabetes mellitus.

摘要

背景

I型糖原贮积病是一种遗传性疾病,与持续性空腹低血糖及无法产生内源性葡萄糖有关。糖原贮积病合并糖尿病的情况极为罕见。这些患者发生糖尿病的潜在发病机制尚不清楚,且尚无治疗指南。

病例介绍

我们描述了一例34岁南亚裔女性I型糖原贮积病患者,其在年轻时发展为未控制的糖尿病。产后发现高血糖,数年后病情恶化。由于其潜在的糖原贮积病存在低血糖风险,糖尿病治疗困难。在低血糖事件极少的情况下,患者通过运动联合钠-葡萄糖协同转运蛋白2抑制剂和α-葡萄糖苷酶抑制剂,血糖得到改善。

结论

我们报告了一例罕见的I型糖原贮积病合并糖尿病病例。根据文献,糖原贮积病与代谢综合征之间似乎存在关联,这可能在发病机制中起作用。血糖控制的管理仍然是一项临床挑战,需要同时处理糖原贮积病引起的空腹低血糖以及糖尿病引起的餐后高血糖。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4836/5682031/38c38796a124/13256_2017_1462_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4836/5682031/a3b1936d4c90/13256_2017_1462_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4836/5682031/e7ef13754e42/13256_2017_1462_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4836/5682031/38c38796a124/13256_2017_1462_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4836/5682031/a3b1936d4c90/13256_2017_1462_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4836/5682031/e7ef13754e42/13256_2017_1462_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4836/5682031/38c38796a124/13256_2017_1462_Fig3_HTML.jpg

相似文献

1
Diabetes mellitus in a patient with glycogen storage disease type Ia: a case report.1型糖原贮积病患者合并糖尿病:一例报告
J Med Case Rep. 2017 Nov 12;11(1):319. doi: 10.1186/s13256-017-1462-5.
2
SGLT2 inhibition alleviated hyperglycemia, glucose intolerance, and dumping syndrome-like symptoms in a patient with glycogen storage disease type Ia: a case report.SGLT2 抑制剂可缓解糖原贮积病 Ia 型患者的高血糖、葡萄糖不耐受和倾倒综合征样症状:病例报告。
J Med Case Rep. 2021 Feb 16;15(1):75. doi: 10.1186/s13256-020-02658-5.
3
Diabetes in a Patient with Glycogen Storage Disease Type 1a.1a 型糖原贮积病患者的糖尿病。
Intern Med. 2024 Aug 1;63(15):2153-2156. doi: 10.2169/internalmedicine.2766-23. Epub 2024 Jan 2.
4
The beneficial effect of α-glucosidase inhibitor on glucose variability compared with sulfonylurea in Taiwanese type 2 diabetic patients inadequately controlled with metformin: preliminary data.与磺酰脲类药物相比,α-葡萄糖苷酶抑制剂在台湾二甲双胍控制不佳的 2 型糖尿病患者中的葡萄糖变异性有益作用:初步数据。
J Diabetes Complications. 2011 Sep-Oct;25(5):332-8. doi: 10.1016/j.jdiacomp.2011.06.004. Epub 2011 Aug 2.
5
The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes.钠-葡萄糖协同转运蛋白2抑制剂在2型糖尿病治疗中的作用
Clin Ther. 2015 Jun 1;37(6):1150-66. doi: 10.1016/j.clinthera.2015.03.004. Epub 2015 Apr 16.
6
Secondary diabetes as a rare complication of glycogen storage disease 1a: case report and review of literature.糖原贮积病 1a 导致的继发性糖尿病:罕见并发症病例报告及文献复习。
Pediatr Endocrinol Diabetes Metab. 2021;27(4):283-286. doi: 10.5114/pedm.2021.109121.
7
Canagliflozin in Conjunction With Sulfonylurea Maintains Glycemic Control and Weight Loss Over 52 Weeks: A Randomized, Controlled Trial in Patients With Type 2 Diabetes Mellitus.卡格列净联合磺脲类药物可在 52 周内维持血糖控制和体重减轻:一项 2 型糖尿病患者的随机对照试验。
Clin Ther. 2017 Nov;39(11):2230-2242.e2. doi: 10.1016/j.clinthera.2017.10.003. Epub 2017 Nov 3.
8
Current understanding on pathogenesis and effective treatment of glycogen storage disease type Ib with empagliflozin: new insights coming from diabetes for its potential implications in other metabolic disorders.目前对依帕列净治疗 1b 型糖原贮积病发病机制和疗效的认识:糖尿病领域的新见解可能对其他代谢性疾病有潜在影响。
Front Endocrinol (Lausanne). 2023 Apr 21;14:1145111. doi: 10.3389/fendo.2023.1145111. eCollection 2023.
9
Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes.钠-葡萄糖共转运蛋白 2 抑制剂坎格列净联合胰岛素治疗 2 型糖尿病患者的疗效和安全性。
Diabetes Care. 2015 Mar;38(3):403-11. doi: 10.2337/dc14-1237. Epub 2014 Dec 2.
10
Type la glycogen storage disease complicated with diabetes mellitus: the role of flash continuous glucose monitoring.糖原贮积病合并糖尿病 1 型:瞬态血糖连续监测的作用。
BMJ Case Rep. 2021 Mar 25;14(3):e240489. doi: 10.1136/bcr-2020-240489.

引用本文的文献

1
Avascular necrosis as an uncommon manifestation in glycogen storage disease type III: diagnostic and therapeutic challenges.无血管性坏死作为Ⅲ型糖原贮积病的一种罕见表现:诊断和治疗挑战
Oxf Med Case Reports. 2025 Aug 20;2025(8):omaf145. doi: 10.1093/omcr/omaf145. eCollection 2025 Aug.
2
Impact of Flash Glucose Monitoring in Adults with Inherited Metabolic Disorders at Risk of Hypoglycemia.实时葡萄糖监测对有低血糖风险的遗传性代谢紊乱成年患者的影响。
Nutrients. 2025 Jan 9;17(2):222. doi: 10.3390/nu17020222.
3
Endocrine involvement in hepatic glycogen storage diseases: pathophysiology and implications for care.

本文引用的文献

1
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS.美国临床内分泌医师协会和美国内分泌学会关于钠-葡萄糖协同转运蛋白2(SGLT-2)抑制剂与糖尿病酮症酸中毒相关性的立场声明
Endocr Pract. 2016 Jun;22(6):753-62. doi: 10.4158/EP161292.PS. Epub 2016 Jun 1.
2
Glycogen storage disease type Ia (GSDIa) but not Glycogen storage disease type Ib (GSDIb) is associated to an increased risk of metabolic syndrome: possible role of microsomal glucose 6-phosphate accumulation.Ia型糖原贮积病(GSDIa)而非Ib型糖原贮积病(GSDIb)与代谢综合征风险增加相关:微粒体6-磷酸葡萄糖蓄积的可能作用。
Orphanet J Rare Dis. 2015 Jul 29;10:91. doi: 10.1186/s13023-015-0301-2.
3
内分泌系统在肝糖原贮积病中的作用:病理生理学及对治疗的意义
Rev Endocr Metab Disord. 2024 Aug;25(4):707-725. doi: 10.1007/s11154-024-09880-2. Epub 2024 Apr 1.
4
Euglycemic Diabetic Ketoacidosis Presenting as Hypoglycemia in a Patient With Type 2 Diabetes and Von Gierke's Disease.在一名2型糖尿病合并冯·吉尔克病患者中,正常血糖性糖尿病酮症酸中毒表现为低血糖症。
Cureus. 2024 Jan 11;16(1):e52104. doi: 10.7759/cureus.52104. eCollection 2024 Jan.
5
Diabetes in a Patient with Glycogen Storage Disease Type 1a.1a 型糖原贮积病患者的糖尿病。
Intern Med. 2024 Aug 1;63(15):2153-2156. doi: 10.2169/internalmedicine.2766-23. Epub 2024 Jan 2.
6
A glycogen storage disease type 1a patient with type 2 diabetes.1a 型糖原贮积病合并 2 型糖尿病患者。
BMC Med Genomics. 2022 Sep 27;15(1):205. doi: 10.1186/s12920-022-01344-3.
7
Secondary diabetes as a rare complication of glycogen storage disease 1a: case report and review of literature.糖原贮积病 1a 导致的继发性糖尿病:罕见并发症病例报告及文献复习。
Pediatr Endocrinol Diabetes Metab. 2021;27(4):283-286. doi: 10.5114/pedm.2021.109121.
8
Type la glycogen storage disease complicated with diabetes mellitus: the role of flash continuous glucose monitoring.糖原贮积病合并糖尿病 1 型:瞬态血糖连续监测的作用。
BMJ Case Rep. 2021 Mar 25;14(3):e240489. doi: 10.1136/bcr-2020-240489.
9
SGLT2 inhibition alleviated hyperglycemia, glucose intolerance, and dumping syndrome-like symptoms in a patient with glycogen storage disease type Ia: a case report.SGLT2 抑制剂可缓解糖原贮积病 Ia 型患者的高血糖、葡萄糖不耐受和倾倒综合征样症状:病例报告。
J Med Case Rep. 2021 Feb 16;15(1):75. doi: 10.1186/s13256-020-02658-5.
Lessons from new mouse models of glycogen storage disease type 1a in relation to the time course and organ specificity of the disease.1a型糖原贮积病新小鼠模型关于疾病病程和器官特异性的经验教训。
J Inherit Metab Dis. 2015 May;38(3):521-7. doi: 10.1007/s10545-014-9761-0. Epub 2014 Aug 28.
4
The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes.肝脏脂质在肝胰岛素抵抗和 2 型糖尿病中的作用。
Nature. 2014 Jun 5;510(7503):84-91. doi: 10.1038/nature13478.
5
Glycogen storage disease type 1 and diabetes: learning by comparing and contrasting the two disorders.糖原贮积病 1 型和糖尿病:比较和对比两种疾病来学习。
Diabetes Metab. 2013 Oct;39(5):377-87. doi: 10.1016/j.diabet.2013.03.002. Epub 2013 May 2.
6
Regulation of hepatic glucose uptake and storage in vivo.体内肝葡萄糖摄取和储存的调节。
Adv Nutr. 2012 May 1;3(3):286-94. doi: 10.3945/an.112.002089.
7
Glucose-6-phosphatase deficiency.葡萄糖-6-磷酸酶缺乏症。
Orphanet J Rare Dis. 2011 May 20;6:27. doi: 10.1186/1750-1172-6-27.
8
Exercise and glucose metabolism in persons with diabetes mellitus: perspectives on the role for continuous glucose monitoring.糖尿病患者的运动与葡萄糖代谢:连续血糖监测作用的观点
J Diabetes Sci Technol. 2009 Jul 1;3(4):914-23. doi: 10.1177/193229680900300439.
9
Pathogenesis of non-alcoholic fatty liver disease.非酒精性脂肪性肝病的发病机制。
QJM. 2010 Feb;103(2):71-83. doi: 10.1093/qjmed/hcp158. Epub 2009 Nov 13.
10
Secondary diabetes mellitus: late complication of glycogen storage disease type 1b.继发性糖尿病:1b型糖原贮积病的晚期并发症。
J Pediatr Endocrinol Metab. 2005 Jun;18(6):617-9. doi: 10.1515/jpem.2005.18.6.617.